[연수강좌]

- 심혈관계 질환의 발생 및 진행과 관련된 유전자 분석의 의미와 이를 바탕으로 한 영양 치료의 적용에 대한 소개 -

성균관의대 강북삼성병원 가정의학과

서 론

SNPs(Single nucleotide polymorphisms) RFLPs (restriction fragments length polymorphisms) 20 . 30 RFLPs . SNPs . SNPs SNPs SNPs (marker) SNPs .

complex genetic disorder . . , . , ( )

, [1]

, , ,

(gene polymorphisms) .

Gene polymorphisms, diet, and cardiovascular disease

, , , , . (multigenic), (multifactorial). , , , .

SNPs .

, .[2]

1. Genes encoding factors involved in atherosclerosis development

. .

, . , .[3]

The future

PKU (phenylketonuria), cystic fibrosis monogenic . , , multigenic, multifactorial disease - - . PKU , (low phenylalanine diet) . (, , ,) . SNPs association study SNPs SNPs . . . , 45 I, II, III . , . , , , .[35] , genomic profiling . genomic profiling , . , - . , . , . personalized lifestyle modification , - , - ( ) . . . - . , , .

참고문헌

1. Ordovas JM. Cardiovascular disease genetics: a long and winding road. Curr Opin Lipidol 2003;14:47-54
2. Ordovas JM, Mooser V. Nutrigenomics and nutrigenetics. Curr Opin in Lipid 2004;15:101-8
3. Loktionov A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases(Review). J Nutr Biochem 2003;14:426-51
4. Masson LF, McNeill G, Avenell A. Genetic variation and the lipid response to dietary intervention: a systematic review. Am J Clin Nutr 2003;77:1098-111
5. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41
6. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Capps NE, Smith GD, Riemersma RA, Ebrahim S. Dietary fat intake and prevention of cardiovascular disease: systemic review. Br Med J 2001;322:757-63
7. Ye SQ, Kwiterovich PO. Influence of genetic polymorphisms on responsiveness to dietary fat and cholesterol. Am J Clin Nutr 2000;52(5 Suppl.):1275S-84S
8. Breslow JL. Genetics of lipoportein abnormalieties associated with coronary heart disease susceptibility. Ann Rev Genet 2000;34:233-54
9. Talmud PJ. Humphries SE. Genetic polymorphisms, lipoproteins and coronary artery disease risk. Curr Opin Lipidol 2001;12:405-9
10. Shohet RV, Vega GL, Bersot TP, Mahley RW, Grundy SM, Guerra r, Cohen JC. Sources of variability in genetic association studies: insights from the analysis of hepatic lipase. Hum Mutat 2002;19:536-42

11. Ordovas JM, Coreella D, Demissie S, Cupples LA, Couture P, Coltell O, Wilson PW, Schaefer EJ, Tucker KL. Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolisms: evidence of a strong dose effect in thes gene-neutrient interaction in the Framingham Study. Circulation 2002;106:2315-21
12. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes(PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44
13. Heinecke JW, Lusis AJ. Paraoxonase gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 1998;62:20-4
14. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscl Thromb Vasc Biol 2002;22:1329-33
15. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, SalonenJT, Alfthan G, Aro A, Kesaniemi YA. Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 2002;132:3012-7
16. Glass CK, Witztum JL. A therosclerosis: The road ahead. Cell 2001;104:503-16
17. Andreotti F, Porto I, Crea f, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002;87:107-12
18. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-Lipoxygenase Pormoter Genotype, Dietary arachidonic acid, and Atherosclerosis. NEJM 2004;350:29-31
19. Caterina RD, Zampolli A. From Asthma to Atherosclerosis-5-Lipoxygenase, Leukotrienes, and inflammation. NEJM 2004;350:4-7
20. Luft FC, Weinberger MH. Heterogeneous responses to changes in dietary salt intake: the salt-sensitivity paradigm. Am J Clin Nutr 1997;65(2 Suppl.):612S-7S
21. Anderson RA, Jones CJ, Goodfellow J. Is the fatty meal a trigger for acute coronary syndromes. Atherosclerosis 2001;159:9-15
22. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable-benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049-57
23. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary heart disease. NEJM 1997;337:230-6
24. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PF, Selhub J, Dmymgostino RB, Wilson PW, Wolf PA. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999;131:352-5
25. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993;87:1107-13
26. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc 1997;277:1775-81
27. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202-8
28. Nallamothu BK, Fendrick AM, Omenn GS. Homocysteine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocysteinaemia. Pharmacoeconomics 2002;20:429-42
29. Refsum H, Ueland PM, Nysd O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62
30. Smith SC Jr, Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. Circulation 2000;101:111-6
31. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32
32. Morris CD, Carson S. Routine Vitamin Supplementation to prevent cardiovascular disease: A summary of the evidence for the U.S.Preventive Services Task Force. Ann Intern Med 2003;139:56-70
33. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Shouten EG. MTHFR 677C→T Polymorphisms and risk of coronary heart disease. A Meta-analysis. JAMA 2002;288:2023-31

34. Burke W, Haga SB, Khoury MJ. Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nature Genetics 2003;34(4):347-50
35. Simopoulos AP. Genetic variation and dietary response: Nutrigenetics/nutrigenomics. Asia Pacific J Clin Nutr 2002;11(S6): S117-28
36. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease. J Am Med Assoc 2003;290:932-40
37. Stranger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M, DACH-LIGA Homocystein e.V. DACH-LIGA homocystein(german, Austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41(11):1392-403